Last reviewed · How we verify

Peplin — Portfolio Competitive Intelligence Brief

Peplin pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PEP005 (ingenol mebutate) Gel PEP005 (ingenol mebutate) Gel phase 3 Protein kinase C (PKC) activator Protein kinase C (PKC) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Forma Therapeutics, Inc. · 1 shared drug class
  3. Icahn School of Medicine at Mount Sinai · 1 shared drug class
  4. LEO Pharma · 1 shared drug class
  5. Padagis LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Peplin:

Cite this brief

Drug Landscape (2026). Peplin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/peplin. Accessed 2026-05-14.

Related